EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computational assessment of gut microbiota metabolite enterolactone as a promising Aβ42 inhibitor in Alzheimer's disease

Skyler Hoang, Emerson Lam, Hue Dao

DYSONA – Life Science · 01.04.2024 · 5 (1) · 9

DOI: 10.30493/dls.2023.419136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift DYSONA – Life Science, online erschienen am 01.04.2024. Verfasst von Skyler Hoang und 2 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging evidence suggests that gut microbiota metabolites can have a potential role in conferring neuroprotective benefits against Alzheimer's disease. Enterolactone, (S)-equol, and urolithin A are bacterial metabolites that originate from rich dietary sources. In this study, the inhibition potential of the aforementioned metabolites on Aβ42 peptide was investigated through molecular dynamics simulations. The study revealed that interacting with metabolites decreases the intra-connectivity of Aβ42, resulting in a reduction in strongly correlated residue pairs and a complete absence of strongly anti-correlated residue pairs. The MM/PBSA binding energy analyses showed that enterolactone had the strongest binding affinity with Aβ42 peptide (-291.0 kJ/mol), while (S)-equol and urolithin A had weaker binding affinities. The study also revealed that enterolactone and (S)-equol have the potential to induce structural perturbations in the Aβ42 peptide, resulting in reduced conformational fluctuations and flexibility. The study suggests that diets rich in matairesinol may inhibit Aβ42 action, as enterolactone is a matairesinol-derived metabolite generated through gut microbiota activity. Additional research is required in order to have a comprehensive understanding of the specific processes that underlie these associations and to develop efficacious supplementary therapy strategies that involve the modulation of gut microbiota and their metabolites.

Zitieren

APA

Hoang, S., Lam, E., & Dao, H. (2024). Computational assessment of gut microbiota metabolite enterolactone as a promising Aβ42 inhibitor in Alzheimer's disease. DYSONA – Life Science, 5(1), 9. https://doi.org/10.30493/dls.2023.419136

Vancouver

Hoang S, Lam E, Dao H. Computational assessment of gut microbiota metabolite enterolactone as a promising Aβ42 inhibitor in Alzheimer's disease. DYSONA – Life Science. 2024;5(1):9. doi:10.30493/dls.2023.419136

BibTeX
@article{Hoang2024,
  author = {Hoang, Skyler and Lam, Emerson and Dao, Hue},
  title = {Computational assessment of gut microbiota metabolite enterolactone as a promising Aβ42 inhibitor in Alzheimer's disease},
  journal = {DYSONA – Life Science},
  year = {2024},
  volume = {5},
  number = {1},
  pages = {9},
  doi = {10.30493/dls.2023.419136}
}
Kostenlos starten →